Skip to Content
Søg Menu

AML-highlights fra ASH22 – i dansk perspektiv

Hans Beier Ommen, overlæge, afdeling for Blodsygdomme, Aarhus Universitetshospital perspektiverer i denne MEDtalk tre udvalgte abstracts herunder brugen af MRD. I MEDtalken finder du links til de tre abstracts, som Hans Beier Ommen perspektiverer fra ASH22.

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Relateret indhold

Gunnar Juliusson

Cytarabine Dose Intensification Improves Survival in Older Patients with AML

/ Gunnar Juliusson
AML Play the Video 08:21

The Development of New Treatment Options within AML Is Slower Than in Other Disease Areas within Hematology

/ BestPractice Nordic
EHA24AML
Nikolaj Nitschke

Functional Characterization for Germline Variants in Patients with MDS and AML

/ Nikolaj Juul Nitschke
EHA24AML Play the Video 03:17

Drug Sensitivity Screening to Guide Clinical Decisions for Hematologic Cancers

/ Sigrid S. Skånland
AMLCLL
Jad Othman

MRD Status in NPM1 Mutated AML Should Be a Part of the Selection of Patients for Transplant in First Remission

/ Jad Othman
ASH23AML Play the Video 03:32

ASH 2023: Oral Decitabine-Cedazuridine Tablet Shows Promise for AML Treatment in Phase III Study

/ BestPractice Nordic
ASH23AML
Sergio Giralt

In the Era of Personalized Treatment and Targeted Therapies

/ Sergio Giralt
ASH23AML Play the Video 2:46

Promising Results from EHA23: Gilteritinib as Posttransplant Maintenance Therapy for FLT3-ITD AML Patients

/ BestPractice Nordic
EHA23AML

FLT3 Inhibitor Gilteritinib Shows Potential in Post-Transplant Maintenance for AML

/ Mark Levis
EHA23AML Play the Video 05:06
Back to top